Toward routine use of non‐steroidal anti‐inflammatory drugs for patients undergoing endoscopic retrograde cholangiopancreatography

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used pharmacological prevention strategy for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). 1,2 Experimental data suggest that NSAIDs, a group of inhibitors of PTGS1 (cyclooxygenase-1 or COX-1) and PTGS2 (cyclooxygenase-2 or COX-2), can prevent PEP through inhibition of phospho